Niacin
- Generic Name
- Niacin
- Brand Names
- Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one
- Drug Type
- Small Molecule
- Chemical Formula
- C6H5NO2
- CAS Number
- 59-67-6
- Unique Ingredient Identifier
- 2679MF687A
- Background
Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.
- Indication
Niacin is indicated to prevent vitamin deficiencies in pediatric and adult patients receiving parenteral nutrition as part of multivitamin intravenous injections. Niacin oral tablets are indicated as a monotherapy or in combination with simvastatin or lovastatin to treat primary hyperlipidemia and mixed dyslipidemia. It can also be used to reduce the risk of nonfatal myocardial infarctions in patients with a history of myocardial infarction and hyperlipidemia. Niacin is also indicated with bile acid binding resins to treat atherosclerosis in patients with coronary artery disease and hyperlipidemia or to treat primary hyperlipidemia. Finally niacin is indicated to treat severe hypertriglyceridemia.
- Associated Conditions
- Atherosclerosis, High Cholesterol, High Triglyceride Level, Mixed Dyslipidemias, Nonfatal Myocardial Infarction, Pellagra, Primary Hypercholesterolemia, Severe Hypertriglyceridemia (sHTG), Type II Hyperlipidaemia
- Associated Therapies
- Dietary supplementation
Effect of an Investigational Compound on Tolerability of Extended Release Niacin (0524A-023)(COMPLETED)
- Conditions
- HypercholesteremiaHyperlipidemia
- Interventions
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 825
- Registration Number
- NCT00376584
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
- Conditions
- Healthy
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00359281
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
The High Density Lipoprotein and Endothelial Function, Niacin and Nitric Oxide Study (The High-Ennd Study)
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-05-06
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 32
- Registration Number
- NCT00346970
- Locations
- 🇩🇪
Hannover Medical School, Hannover, Germany
Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
- Conditions
- HyperlipidemiaMixed HyperlipidemiaDyslipidemia
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2006-06-28
- Lead Sponsor
- In His Image
- Target Recruit Count
- 100
- Registration Number
- NCT00345657
- Locations
- 🇺🇸
Family Medical Care of Tulsa, Tulsa, Oklahoma, United States
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
- Conditions
- Insulin ResistanceMetabolic Syndrome X
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2006-03-21
- Lead Sponsor
- Foundation Research, Florida
- Target Recruit Count
- 30
- Registration Number
- NCT00304993
- Locations
- 🇺🇸
Foundation Research, St. Petersburg, Florida, United States
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
- Conditions
- Metabolic Syndrome
- Interventions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2017-07-28
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 38
- Registration Number
- NCT00300365
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Exercise Versus Niacin in Patients With Coronary Artery Disease (CAD) and Low High-Density Lipoproteins (HDL)
- Conditions
- Coronary DiseaseHypolipoproteinemia
- Interventions
- First Posted Date
- 2006-03-03
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- University of Leipzig
- Target Recruit Count
- 48
- Registration Number
- NCT00298909
- Locations
- 🇩🇪
University of Leipzig Heart Center, Leipzig, Germany
Niacin, N-3 Fatty Acids and Insulin Resistance
- Conditions
- HypertriglyceridemiaMetabolic Syndrome
- Interventions
- First Posted Date
- 2006-02-03
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- University of South Dakota
- Target Recruit Count
- 68
- Registration Number
- NCT00286234
- Locations
- 🇺🇸
Sanford Clinic Clinical Research Services, Sioux Falls, South Dakota, United States
Lipid Efficacy Study (0524B-022)(COMPLETED)
- Conditions
- Primary HypercholesterolemiaMixed Hyperlipidemia
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1400
- Registration Number
- NCT00269217
Lipid Efficacy/Tolerability Study (0524A-020)
- Conditions
- Primary HypercholesterolaemiaMixed Hyperlipidaemia
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1620
- Registration Number
- NCT00269204
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.